| Autor: |
Vidal-Neira LF; Rheumatology Service, Centro Diagnóstico de la Osteoporosis y Enfermedades Óseas, Lima, Perú., Neyro JL; University of Madrid (UDIMA), Madrid, España., Maldonado G; Rheumatology Service, Vanderbilt University Medical Center, Nashville, TN, USA., Messina OD; Gynecology Service, Investigaciones Reumatológicas y Osteológicas Medical Center, Buenos Aires, Argentina., Moreno-Alvarez M; Rheumatology Service, Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador., Ríos C; Rheumatology Service, Centro de Reumatología y Rehabilitación, Guayaquil, Ecuador. |
| Abstrakt: |
Fibromyalgia (FM) and climacteric conditions share common epidemiological and clinical features, with FM symptoms often beginning during menopause. Musculoskeletal pain, arthralgia, myalgia and other symptoms are frequently seen in both conditions. Some research suggests a link between the cessation of sex hormones and FM symptoms. Women with FM tend to experience more severe symptoms after menopause, and the severity of FM symptoms can worsen in women who have had a hysterectomy with or without oophorectomy. Despite these similarities, it is essential to treat FM and climacteric conditions separately and follow established guidelines for management. However, it is also important to recognize that both conditions can coexist in the same patient. It is crucial to note that there is limited evidence supporting the effectiveness of menopausal hormone therapy for primary FM management. Therefore, menopausal hormone therapy should not be recommended for FM unless the patient also has climacteric syndrome. |
